摘要

Purpose: To determine if exogenous addition of tumor necrosis factor alpha (TNF alpha) exacerbates retinal reactive gliosis in an organotypic culture of porcine neuroretina and to evaluate if concomitant adalimumab, a TNF-blocker, diminishes it. %26lt;br%26gt;Methods: Porcine retinal explants from 20 eyeballs were cultured. Cultures with 100 pg/ml TNF alpha, 10 mu g/ml adalimumab, 100 pg/ml TNF alpha plus 10 mu g/ml adalimumab, or controls without additives were maintained for 9 days. Freshly detached retinas were processed in parallel. TNF alpha levels in control culture supernatants were quantified with enzyme-linked immunosorbent assay. Cryostat sections were doubly immunostained for glial fibrillary acidic protein (GFAP), a marker for reactive gliosis, and cellular retinaldehyde-binding protein (CRALBP), a marker for Muller cells. Sections were also labeled with the isolectin IB4, a label for microglia/macrophages. %26lt;br%26gt;Results: TNF alpha in control culture supernatants was detected only at day 1. Compared to the fresh neuroretinal samples, upregulation of GFAP and downregulation of CRALBP occurred during the 9 days of culture. Exogenous TNF alpha stimulated glial cells to upregulate GFAP and downregulate CRALBP immunoreactivity. TNF alpha-treated cultures also initiated the growth of gliotic membranes and underwent retinal disorganization. Adalimumab inhibited the spontaneous increases in GFAP and maintained CRALBP. In combination with TNF alpha, adalimumab reduced GFAP expression and conserved CRALBP, with only slight retinal disorganization. No appreciable changes in IB4 labeling were observed under the different culture conditions. %26lt;br%26gt;Conclusions: In cultured porcine neuroretina, spontaneous reactive gliosis and retinal disorganization were exacerbated by exogenous TNF alpha. Adalimumab reduced spontaneous changes and those induced by TNF alpha. Therefore, inhibiting TNF alpha may represent a novel approach to controlling retinal fibrosis observed in some human diseases.

  • 出版日期2013-4-17